 SAN DIEGO, April 06, 2022 GLOBE NEWSWIRE -- Travere Therapeutics, Inc. NASDAQ: TVTX today announced that the Company will present data from the ongoing Phase 12 COMPOSE Study of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated for the treatment of classical homocystinuria HCU, at the Society for Inherited Metabolic Disorders SIMD 43rd Annual Meeting, and the 2022 Genetic Metabolic Dieticians International GMDI Conference. In December 2021, the Company announced positive topline results from the COMPOSE Study. The Company and its collaborators will also present real-world evidence from metabolic centers of excellence on current challenges in the dietary management of classical HCU. 